phrykt

Sangamo Therapeutics, Inc (SGMOQ): who owns it and who trades it

As of Nov 16, 2026, SGMOQ insiders reported 2 open-market sales worth $107K and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Nathalie Dubois-Stringfellow (Vice president), with $89.9K.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Insider trades

In the last 12 months, SGMOQ insiders reported $0 of open-market purchases and $107K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$107K
2 trades, 2 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Apr 22, 2026
Filed Apr 23, 2026

Purchases and sales by month

$107K$107KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Apr 22, 2026Gregory D DavisHead of Research & TechnSale69,827$0.25$17.5KForm 4
Apr 21, 2026Nathalie Dubois-StringfellowVice presidentSale345,942$0.26$89.9KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Nathalie Dubois-StringfellowSVP-CHIEF DEVELOPMENT OFFICER–$89.9KApr 21, 2026
Gregory D DavisHead of Research & Technology–$17.5KApr 22, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

SGMOQ short interest

8.35M SGMOQ shares are sold short. Over the last 9 reports the number of shares short went down 47%.

As of Oct 30, 2026, 8.35M SGMOQ shares were sold short, down 2.1% from the report before. At the average daily volume of 1.71M shares, buying them all back would take about 4.9 trading days (days to cover).

Shares short, % of all shares

2.25%Jun 30Sep 304.08%

Days to cover

4.9Jun 30Oct 305.5

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20268.35M–-2%1.71M4.9
Oct 15, 20268.52M–-8%3.35M2.5
Sep 30, 20269.31M2.25%-13%2.79M3.3
Sep 15, 202610.72M2.59%+3%3.32M3.2
Aug 31, 202610.43M2.52%+5%6.19M1.7
Aug 14, 20269.94M2.40%-4%8.65M1.1
Jul 31, 202610.34M2.50%-1%4.54M2.3
Jul 15, 202610.48M2.53%-34%7.95M1.3
Jun 30, 202615.90M3.84%-36%24.28M1.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Sangamo Therapeutics company events

Sangamo Therapeutics filed 16 reports on Form 8-K in the last 12 months, 8 of them about an important change (leadership, listing, bankruptcy). The latest was on Oct 27, 2026.

  1. Oct 27, 2026AnnouncementShared information with investors. Filing
  2. Oct 16, 2026AnnouncementShared information with investors. Filing
  3. Sep 21, 2026BankruptcyThe information set forth under Item 2.01 below is incorporated into this Item 1.03 by reference. Filing
  4. Sep 8, 2026BankruptcyThe information set forth under Item 2.01 below is incorporated into this Item 1.03 by reference. Filing
  5. Aug 28, 2026BankruptcyOf this Current Report on Form 8-K under the heading “PTC Asset Purchase Agreement” is incorporated herein by reference. Filing
  6. Aug 13, 2026AnnouncementAs previously announced, on June 23, 2026, Sangamo Therapeutics, Inc. filed a voluntary petition for relief under Chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the District of Delaware, thereby commencing a Chapter 11 case for the Company. Filing
  7. Aug 12, 2026AnnouncementShared information with investors. Filing
  8. Jul 20, 2026BankruptcyAs previously disclosed, on June 23, 2026, Sangamo Therapeutics, Inc. filed a voluntary petition (Case No. 26-10989) for relief under Chapter 11 of the Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (such court, the “Court” and such case, the “Case”). Filing
  9. Jul 1, 2026AuditorChange in Registrant’s Certifying Accountant. Filing
  10. Jun 23, 2026BankruptcyOf this Current Report on Form 8-K under the heading “Stalking Horse Asset Purchase Agreements” is incorporated herein by reference. Filing
  11. May 14, 2026ResultsReleased financial results. Filing
  12. Apr 29, 2026ListingGot a notice from its stock exchange about its listing, or moved its listing. Filing
  13. Mar 30, 2026ResultsReleased financial results. Filing
  14. Feb 4, 2026AgreementSangamo Therapeutics, Inc. entered into an underwriting agreement with Cantor Fitzgerald & Co. and Wells Fargo Securities, LLC, as representatives of the several underwriters named therein, relating to the issuance and sale of 35,190,292 shares of the Company’s common stock, par value $0.01 per… Filing
  15. Feb 3, 2026AnnouncementSangamo Therapeutics, Inc. announced the presentation of clinical data from its registrational Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for the treatment of Fabry disease, in four clinical and nonclinical platform and… Filing
  16. Feb 3, 2026LeadershipThe employment of Prathyusha Duraibabu, the Company’s principal financial officer, terminated. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Sangamo Therapeutics financials

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named SGMOQ in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Armistice Capital, LLC13G/A9.8%
Nov 16, 2026Armistice Capital, LLC13G/A9.8%

Questions about Sangamo Therapeutics, Inc (SGMOQ) stock

Are SGMOQ insiders buying or selling?

In the last 12 months, SGMOQ insiders reported no open-market purchases and 2 sales worth $107K. The latest trade was on Apr 22, 2026. See every trade.

What is the short interest in SGMOQ?

As of Oct 30, 2026, 8.35M SGMOQ shares were sold short, down 2.1% from the report before. At the average daily volume of 1.71M shares, buying them all back would take about 4.9 trading days (days to cover). See the history.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.